Janux Therapeutics, Inc.
JANX
Positions held
Your positionsJANX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Janux Therapeutics is positioned in the innovative biotechnology sector, focusing on developing novel therapies that could address unmet medical needs.
- Revenue increased by 175% compared to the prior quarter, reaching $10 million from $3.7 million.
- The operating margin improved to -308.7%, indicating a potential for operational efficiency.
- The company has a high debt-to-equity ratio of 2.262, which may pose financial risks.
- Janux reported a net income loss of -21.972 million in Q2 2026, reflecting ongoing financial challenges.
- The forward P/E ratio is -6.40, suggesting that the market has low expectations for future earnings.
Fundamentals
| Market cap | $1.13B | Enterprise value | $181.11M | Trailing P/E | — | Forward P/E | -7.05 |
| PEG | — | Price / book | 1.22 | Beta | 2.39 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | -3.1% |
| Profit margin | 0.0% | ROE | -10.7% | ROA | -8.8% | Debt / equity | 0.02 |
| Current ratio | 16.35 | Free cash flow | -$16.39M | Analyst recommendation | none | Mean target | $36.24 |
| 52w high | $35.34 | 52w low | $12.12 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $10.3M | $3.7M | $0.0M | $10.0M | $0.0M |
| Op margin | -308.7% | -916.5% | — | -352.5% | — |
| Net income | -$22.0M | -$24.4M | -$31.9M | -$24.3M | -$33.9M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$31.7M | -$34.2M | -$42.4M | -$35.3M | -$45.1M |
- Revenue +175% vs prior quarter ($10M vs $3.7M).
- Operating margin expanded to -308.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $10.0M | $10.6M | $8.1M | $8.6M | — |
| Op margin | -1576.7% | -933.6% | -902.9% | -779.0% | — |
| Net income | -$114M | -$69.0M | -$58.3M | -$63.1M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$158M | -$98.8M | -$73.0M | -$67.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
2026-09-29 · Is Janux’s Dual JANX013–JANX007 Trial Advancing a Durable Precision Oncology Platform for JANX?
2026-09-27 · Janux Therapeutics (JANX) Advances Prostate Cancer Trial While Valuation Still Looks Pricey
2026-09-16 · The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
2026-09-15 · 4 Prostate Cancer Drug Stocks to Watch During Awareness Month
2026-09-14 · Janux Therapeutics Doses First Participant in Phase 1 Study of Prostate Cancer Candidate
2026-09-14 · Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
2026-08-24 · Chipotle downgraded, Darden upgraded: Wall Street's top analyst calls
2026-08-21 · JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
2026-08-11 · Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile
2026-08-10 · RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating
Price (daily)
Full chart · RSI · MACD · patterns